Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 1;109(10):3373-3378.
doi: 10.3324/haematol.2024.284968.

PD-1 blockade and allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma, a matter of time: a national study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire

Eleonore Kaphan  1 , Francois Bettega  2 , Nicolas Vallet  3 , Nathalie Fegueux  4 , Marie Robin  5 , Ali Bazarbachi  6 , Stephanie Nguyen  7 , David Beauvais  8 , Edouard Forcade  9 , Maria Carolina Montes De Oca  10 , Raynier Devillier  10 , Patrice Chevallier  11 , Michael Loschi  12 , Anne Huynh  13 , Jacques-Olivier Bay  14 , Marie-Therese Rubio  15 , Felipe Suarez  16 , Sylvie Francois  17 , Xavier Poire  18 , Nathalie Contentin  19 , Deborah Desmier  20 , Amandine Charbonnier  21 , Jerome Cornillon  22 , Sylvain Chantepie  23 , Pascal Turlure  24 , Claude-Eric Bulabois  25 , David Michonneau  26 , Alban Villate  3 , Sfgm-Tc  27
Affiliations

PD-1 blockade and allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma, a matter of time: a national study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire

Eleonore Kaphan et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Comparison of outcomes in whole cohort, between PD1 blockade and no PD1 groups. Comparison of (A) all grades acute graft-versus-host disease (GVHD) (days) and (B) chronic GVHD (months) in PD1 blockade and no PD1 blockade cohorts. (C) GVHD-relapse free survival (GRFS) in PD1 blockade and no PD1 blockade cohorts. CI: cumulative incidence.
Figure 2.
Figure 2.
Comparison of outcomes depending on delay from last PD1 blockade injection to allogeneic stem cell transplantation. Cumulative incidence (CI) of (A) acute graft-versus-host disease (aGVHD) grade ≥II, (B) severe aGVHD (grades III and IV) depending on delay (days), (C) chronic GVHD (cGVHD) (months) and (D) GVHD relapse-free survival (GRFS) (months) from last PD1 blockade injection to allogeneic stem cell transplantation (allo-SCT). CPI: checkpoint inhibitor.
See this image and copyright information in PMC

References

    1. Martínez C, Carpio C, Heras I, et al. . Potential survival benefit for patients receiving allogeneic hematopoietic stem cell transplantation after nivolumab therapy for relapse/refractory Hodgkin lymphoma: real-life experience in Spain. Biol Blood Marrow Transplant. 2020;26(8):1534-1542. - PubMed
    1. Sarina B, Castagna L, Farina L, et al. . Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood. 2010;115(18):3671-3677. - PubMed
    1. Ijaz A, Khan AY, Malik SU, et al. . Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transplant. 2019;25(1):94-99. - PMC - PubMed
    1. Przepiorka D, Weisdorf D, Martin P, et al. . 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825-828. - PubMed
    1. Jagasia MH, Greinix HT, Arora M, et al. . National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21(3):389-401.e1. - PMC - PubMed

Substances